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Changes in the incidence of candidemia and related
mortality in patients with hematologic malignancies
in the last ten years. A SEIFEM 2015-B report
The epidemiology of invasive fungal infections (IFI)
among patients with hematologic malignancies who are
undergoing either conventional chemotherapy or
hematopoietic stem cell transplantation (HSCT) is chang-
ing due to the introduction of new, effective antifungal
agents for both prophylaxis and treatment which have
markedly reduced aspergillosis and candidiasis.1-3
In this retrospective, multicenter study, we analyzed
the incidence and mortality of candidemia among
patients who were either undergoing chemotherapy
because of various hematologic malignancies or HSCT
(autologous or allogeneic). The results were compared
with those observed in our two previous studies in the
same categories of patients to verify any epidemiological
changes.4,5
This study was conducted between January 2011 and
December 2015 in 23 hematology wards located
throughout Italy which were participating in the SEIFEM
(Sorveglianza Epidemiologica Infezioni Fungine in Ematologia
– Epidemiological Surveillance of Fungal Infections in
Hematology) consortium. Enrollment was limited to
patients with acute myeloid or lymphoid leukemia (AML
and ALL, respectively), non-Hodgkin lymphoma (NHL),
or multiple myeloma (MM), excluding those patients
who underwent HSCT who were analyzed separately.
Due to the very low incidence of IFI, particularly can-
didemia, in our previous epidemiological studies,4
patients with Hodgkin lymphoma, chronic leukemia and
other chronic myeloproliferative disorders were excluded
from this study. Recipients of either autologous or allo-
geneic HSCT were analyzed. 
Each participating center completed a form, which
included information on all patients who were admitted
to the participating hematology departments and had
developed a positive blood culture for Candida spp. dur-
ing the study period. As a general rule, we collected infor-
mation on all patients who had a diagnosis of the select-
ed malignancies during the study period.
Mortality was considered attributable to candidemia
when patients died within 12 weeks of the onset of fever
and had microbiological, histological or clinical evidence
of active candidemia and when any alternative cause had
been excluded. The attributable mortality rate was calcu-
lated on the whole population of patients, while the case
fatality rate was calculated on patients with candidemia. 
Eighteen of the 23 hematology centers participating in
the present study had also participated in the previous
SEIFEM epidemiological studies on IFI in patients with
hematologic malignancies and HSCT during the period
between 1999-2003.4,5 The reported candidemia inci-
dence and mortality rates during the two study periods
were compared. 
Statistical analyses were performed with Intercooled
Stata software, version 11, for Windows (Stata
Corporation, College Station, TX, USA).
During the study period, 16,529 patients with hemato-
logic malignancies were admitted to the participating
centers for conventional chemotherapy. The patients suf-
fered from AML in 4,581 cases, ALL in 954 cases, either
high- or low-malignancy NHL in 8,452 cases and MM in
2,542 cases. A total of 135 patients developed can-
didemia, for an overall incidence of 0.8%. The incidence
in the different subsets of patients ranged from 0.3%
among patients with MM to 1.6% in patients with ALL.
Among the 135 patients with candidemia, 63% of the
infections occurred in patients with acute leukemia (52%
in AML, 11% in ALL) (Table 1). The attributable mortal-
ity rate was 0.18% (30/16,259), ranging from 0% in ALL
to 0.3% in AML. The case fatality rate in patients with
candidemia was 22% (30/135), ranging from 0/15 (0%)
in ALL to 6/8 (75%) in MM. 
During the same period of observation, 6,928 patients
underwent HSCT (autologous in 4,338 patients and allo-
geneic in 2,590 patients) (Table 2). Of these patients, 59
developed candidemia, for an overall incidence of 0.85%:
21 of the autologous HSCT recipients developed can-
didemia (0.48%) and 38 of the allogeneic HSCT recipi-
ents developed candidemia (1.5%) (Table 2). The attrib-
utable mortality rate for candidemia was 0.16%
(11/6,928), 0.04% in the autologous HSCT recipients
(2/4,338) and 0.34% (9/2,590) in the allogeneic HSCT
recipients. The overall case fatality rate in patients with
candidemia was 18.6% (11/59); the case fatality rate was
9.5% (2/21) in autologous HSCT recipients and 24%
(9/38) in those undergoing an allogeneic HSCT proce-
dure. 
In the first study, a total of 9,258 patients who received
conventional chemotherapy were examined (3,012 with
AML, 1,173 with ALL, 3,457 with NHL, and 1,616 with
MM), while the second study included 3,228 transplant-
ed patients (1,979 autologous HSCT recipients and 1,249
allogeneic HSCT recipients) (Tables 1 and 2). Although a
statistically significant reduction in the incidence of can-
didemia was observed in the overall population over time
[170/9,258 (1.8%) versus 135/16,529 (0.8%); P<0.0001;
95% confidence interval (CI): 1.41-1.73], we could con-
firm this difference only in the subgroup of patients with
AML [124/3,012 (4.1%) versus 70/4,581 (1.5%); P<0.001;
CI: 1.46-1.82]. No differences in the overall incidence of
candidemia (30/3,228 (0.92%) versus 59/6,928 (0.85);
P=0.69) emerged in the recipients of HSCT, in the sub-
group of autologous HSCT recipients [16/1,979 (0.8%)
versus 21/4,338 (0.48%); P=0.12] or in the subgroup of
allogeneic HSCT recipients [14/1,249 (1.1%) versus
38/2,590 (1.5%); P=0.38]. 
Regarding the attributable mortality, an overall signifi-
cant reduction was observed in both patients treated
with conventional chemotherapy [57/9,258 (0.6%) versus
30/16,529 (0.18%); P<0.001; CI: 157-2.13] and in
patients treated using transplant procedures [15/3,228
(0.46%) versus 11/6,928 (0.16%); P<0.004; CI: 1.31-2.57].
The mortality attributable to candidemia in patients who
were treated with conventional chemotherapy was influ-
enced by the marked reduction of mortality among
patients with acute leukemia, both AML [44/3,012
(1.5%) versus 14/4,581 (0.3%); P<0.001; CI: 1.66-2.23]
and ALL [8/1,173 (0.7%) versus 0/954 (0%); P=0.01; CI:
1.75-1.89]; in contrast, no differences were observed in
the groups of patients with NHL or MM. Among the
transplant population, a significantly lower mortality rate
was observed only in recipients of autologous HSCT
[7/1,979 (0.35%) versus 2/4,338 (0.04%);  P=0.002; CI:
1.75-3.53].
The case fatality rate in patients with candidemia after
conventional chemotherapy was significantly lower in
the present cohort than in historical controls [57/170
(34%) versus 30/135 (22%); P<0.03; CI: 1.03-1.54]. In par-
ticular, the case fatality rates were significantly lower
[44/124 (35%) versus 14/70 (20%); P=0.02; CI: 1.05-1.58]
in both the AML and ALL subgroups [8/22 (36%) versus
0/15 (0%); P=0.008; CI: 1.42-3.02]. In contrast, no differ-
ences were detected in the NHL and MM subgroups
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[4/21 (19%) versus 10/42 (24%); P=0.66, and 1/3 (33%)
versus 6/8 (75%); P=0.20, respectively]. 
The reduction of case fatality rates in transplant recip-
ients was more significant for the overall group of recipi-
ents [15/30 (50%) versus 11/59 (18.6%); P=0.002; CI: 1-
39-4.20], for autologous HSCT recipients [7/16 (44%)
versus 2/21 (9.5%); P=0.01; CI: 1.27-4.59] and for allo-
geneic HSCT recipients [8/14 (57%) versus 9/38 (24%);
P=0.02; CI: 1.13-6.66].
For many years, candidemia has been one of the most
relevant IFI in patients with hematologic malignancies,
with a high mortality rate.6-8 Recent reports have shown
that the incidence of candidemia is lower than in past
years, probably because of the use of more effective pro-
phylactic and/or therapeutic antifungal approaches.1-3
Our epidemiological study compared two large multi-
center cohorts of patients with hematologic malignancies
who were treated with conventional chemotherapy or
transplantation procedures during two different periods
(before and after the introduction of the clinical practice
of echinocandins and the latest-generation azoles,
voriconazole and posaconazole). We observed that the
overall incidence of candidemia in patients treated with
conventional chemotherapy has decreased significantly,
being markedly influenced by a relevant reduction of
candidemia in AML patients. In contrast, among patients
with lymphoproliferative diseases, no differences were
observed between the two periods of observation. One
potential explanation for this is that the cohort of AML
patients who were treated between 1999-2003 received
fluconazole, itraconazole, or topical polyenes as antifun-
gal prophylaxis, whereas, since 2010, posaconazole pro-
phylaxis has been used in the majority (close to 90%) of
AML patients on induction chemotherapy in our institu-
tions. As reported, posaconazole has contributed to
reducing the incidences of mold infections and all IFI in
AML patients compared to the incidences in correspon-
ding patients treated with itraconazole/fluconazole.9
Given the low incidence of Candida infections in that
study, little attention was dedicated to the prophylactic
effect of the posaconazole prophylaxis on candidemia,
while the main focus was on its marked efficacy against
aspergillosis.9 Nevertheless, posaconazole also seems to
have the ability to prevent candidemia in patients who
are undergoing transplant procedures. It is worth noting
that in both the compared periods of the surveys, flu-
conazole was the most widely used drug for antifungal
prophylaxis during pre-engraftment neutropenia, since
posaconazole was indicated only for allogeneic HSCT
with graft-versus-host disease.10 However, the most
recent guidelines from the Infectious Diseases Society of
America have extended the use of antifungal prophylaxis
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Table 1. Incidence, attributable mortality and case fatality rate among patients with hematologic malignancies enrolled in two cohorts (his-
torical cohorts and present study)
                                                        Historical cohorts (1999-2003)                                                          Present survey (2011-2015)
                           Patients            Candidemia                  AM                CFR         Patients       Candidemia          AM                CFR               P-value
                                                                        124                                                                                                            70                                                                           <0.001
                                                                     (4.1%)                                                                                                     (1.5%)
AML                          3012                                                               44                                           4581                                                 14                                                <0.001
                                                                                                        (1.5%)                                                                                            (0.3%)
                                                                                                                                    44/124                                                                                             14/70                     0.02
                                                                                                                                    (35%)                                                                                             (20%)                        
                                                                         22                                                                                                             15                                                                              0.60
                                                                     (1.9%)                                                                                                     (1.6%)
                                     1173                                                                8                                              954                                                   0                                                    0.01
ALL                                                                                               (0.7%)                                                                                              (0%)
                                                                                                                                      8/22                                                                                                 0/15                     0.008
                                                                                                                                    (36%)
                                                                        21                                                                                                             42                                                                              0.45
                                                                     (0.6%)                                                                                                     (0.5%)
                                     3457                                                                4                                             8452                                                 10                                                   0.97
NHL                                                                                              (0.1%)                                                                                            (0.1%)
                                                                                                                                      4/21                                                                                                10/42                     0.66
                                                                                                                                    (19%)                                                                                             (24%)
                                                                          3                                                                                                                8                                                                               0.43
                                                                     (0.2%)                                                                                                     (0.3%)
                                     1616                                                                1                                             2542                                                  6                                                    0.18
MM                                                                                              (0.06%)                                                                                           (0.2%)
                                                                                                                                       1/3                                                                                                   6/8                        0.20
                                                                                                                                    (33%)                                                                                             (75%)
                                                                        170                                                                                                           135                                                                          <0.001
                                                                     (1.8%)                                                                                                     (0.8%)
                                     9258                                                               57                                           16529                                                30                                                <0.001
TOTAL                                                                                        (0.6%)                                                                                           (0.18%)
                                                                                                                                    57/170                                                                                             30/135
                                                                                                                                   (34%)                                                                                             (22%)                    0.03
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; MM: multiple myeloma; AM: attributable mortality; CFR: case fatality rate.
with posaconazole to all phases of allogeneic HSCT, so a
significant reduction in the incidence of candidemia in
recipients of such transplants would be expected.11
In both cohorts in the present study the small number
of deaths due to Candida observed in AML patients sig-
nificantly influenced the overall attributable mortality.
Conversely, there were no cases of attributable mortality
observed among the 15 ALL patients with candidemia.
This is important because no other reports so far have
analyzed such data in a large population of patients with
hematologic malignancies. Of interest, there were very
few patients with MM in both the study periods, but in
the present study, 6/8 of the infected MM patients died
because of candidemia. These data are not surprising
because the use of empirical antifungal treatment is more
frequent in patients with AML or ALL than in patients
with MM or NHL. Furthermore, all of the patients with
MM who died were in an unresponsive stage of their dis-
ease (refractory or multi-relapsed status), which may
have compromised the ability of their immune systems
to control the Candida infection. Furthermore, three of
the patients died without receiving antifungal agents. 
Finally, the following additional factors should be
taken into account: (i) antifungal prophylaxis with
posaconazole in AML may have contributed to reducing
the incidence of candidemia in these patients; (ii) the use
of more effective anti-yeast drugs, such as caspofungin,
an echinocandin derivative, was more frequent in the
present study, in sharp contrast with our previous stud-
ies; and (iii) liposomal amphotericin B was the most fre-
quent polyene administered in the current study, where-
as its rate of administration in our previous study was
less than 10%. We could hypothesize that all of these fac-
tors contributed in different ways to reducing the inci-
dence of candidemia in patients with hematologic malig-
nancies in our recent study.
In conclusion, the present study shows that can-
didemia is currently a less relevant problem than it was
in the past in patients with hematologic malignancies,
specifically in those with AML. Candidemia is still a con-
cern in patients with lymphoproliferative malignancies,
to whom antifungal prophylaxis is usually not given, in
part because the introduction of new immune-modulat-
ing drugs (e.g., monoclonal antibodies, tyrosine kinase
inhibitors) might increase the incidence of fungal infec-
tions, including candidemia.
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Table 2. Incidence, attributable mortality and case fatality rate among patients who underwent transplant procedures (autologous and allo-
geneic) enrolled in two cohorts (historical and present study)
                                                        Historical cohorts (1999-2003)                                                          Present survey (2011-2015)
                           Patients            Candidemia                  AM                CFR         Patients       Candidemia          AM                CFR               P-value
                                                                        16                                                                                                             21                                                                              0.12
                                                                     (0.8%)                                                                                                    (0.48%)
Autologous           1979                                                                7                                             4338                                                  2                                                   0.002
HSCT                                                                                          (0.35%)                                                                                          (0.04%)
                                                                                                                                      7/16                                                                                                 2/21                      0.01
                                                                                                                                    (44%)                                                                                            (9.5%)
                                                                         14                                                                                                             38                                                                              0.38
                                                                     (1.1%)                                                                                                     (1.5%)
                                     1249                                                                8                                             2590                                                  9                                                    0.20
Allogeneic                                                             (0.64%)                                                                         (0.34%)
HSCT                                                                                                                         8/14                                                                                                 9/38                      0.02
                                                                                                                                    (57%)                                                                                             (24%)
                                                                         30                                                                                                             59                                                                              0.69
                                                                    (0.92%)                                                                                                   (0.85%)
                                     3228                                                               15                                            6928                                                 11                                                  0.004
TOTAL                                                                                       (0.46%)                                                                                          (0.16%)
                                                                                                                                     15/30                                                                                               11/59                    0.002
                                                                                                                                   (50%)                                                                                           (18.6%)                      
AM: attributable mortality; CFR: case fatality rate.
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